Home Font Size: 1 2 3 Send to a Friend
Source: Eisai Inc.
Contact: Judee Shuler
Eisai Inc.
During ASCO: 908-337-2540
Office: 201-746-2241
Clinical Data on Eisai’s Oncology Pipeline
to be Presented at ASCO Annual Meeting
Diversity of abstracts reflects continued growth of Eisai’s commitment to oncology
Woodcliff Lake, NJ, May 31, 2007– Eisai announced today that several abstracts covering clinical data about their oncology pipeline compounds have been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting. ASCO takes place in Chicago from June 1-5, 2007.
These abstracts reveal a growing and diverse oncology clinical development program at Eisai. In addition to the variety of oncology product classes under investigation, these compounds are being studied in advanced diseases where there remains considerable unmet medical need, particularly in refractory metastatic breast cancer, advanced non-small cell lung cancer, and advanced ovarian cancer.
The following abstracts highlight data from pipeline compounds that have been accepted for presentation at this year’s ASCO meeting.
Product
Abstract Details
Location Details
Eribulin Mesylate (E7389)
Abstract No: 1034
Phase II Study of Eribulin Mesylate (E7389) Halichondrin B Analog in Patients with Refractory Breast Cancer
Poster number 21
June 2, 2007 8:00 AM - 1:00 PM
Location: S403
Abstract No: 7546
Phase II Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Non-Small Cell Lung Cancer (nsclc)
Poster number 20
Location: E451a
MORAb-003
Abstract No: 5583
Novel Phase 2 Study Design of MORAb-003, a Monoclonal Antibody against Folate Receptor Alpha in Platinum-Sensitive Ovarian Cancer in First Relapse
Poster Number: U4
June 2, 2007 2:00 PM - 6:00 PM
Location: S Hall A2
Abstract No: 5553
A Phase 1 study of MORAb-003, a fully humanized monoclonal antibody against folate receptor alpha, in advanced epithelial ovarian cancer
Poster Number: R7
E7974
Abstract No: 2550
A phase I trial of E7974 administered on Days 1 and 15 of a 28-day cycle in patients with solid malignancies
Poster Number: B6
June 3, 2007 8:00 AM - 12:00 PM
Abstract No: 2543
A phase I trial of E7974 administered on Days 1, 8, and 15 of a 28-day cycle in patients with solid malignancies
Poster Number: A13
The expansion of Eisai’s oncology discovery, research and clinical development capabilities complements the company’s establishment of its oncology sales and marketing operations in the United States. Through its acquisition in 2006 of four marketed oncology products, Eisai also obtained key oncology personnel and expertise, including a sales force. Most recently, Eisai acquired Morphotek, Inc., which discovers and develops therapeutic monoclonal antibodies through its proprietary technologies. Morphotek has preclinical and clinical development programs underway in several therapeutic categories, including oncology. Both acquisitions expand Eisai’s capabilities into the biologic therapeutics field.
Eisai is committed to building its commercial oncology infrastructure and is well positioned to market new oncology products that originate from its research and discovery efforts or through future acquisition, co-promotion or in-licensing opportunities. That growth will help Eisai address the unmet medical needs of patients, especially cancer patients, throughout the world.
About Eisai Inc. Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2.6billion in fiscal year 2006 (year ended March 31, 2007). Eisai Inc. employs approximately 1,500 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. For more information about Eisai, please visit www.eisai.com.
About Eisai Medical Research Inc.
Eisai Medical Research Inc., a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., headquartered in Ridgefield Park, NJ, is focused on clinical drug development of new chemical entities and of new indications for marketed products.
About Morphotek, Inc.
Morphotek®, Inc., a U.S. subsidiary of Eisai Co., Ltd., was acquired by Eisai in April 2007. Founded in 2000 and located in Exton, Pennsylvania, Morphotek is a biopharmaceutical company which discovers and develops monoclonal antibodies through the use of proprietary human antibody technology called Human MORPHODOMA®. Morphotek has assembled a strong pipeline of lead products in the areas of oncology and inflammation and infectious diseases. It has programs in clinical development and in preclinical stage moving towards IND filing. For further information, visit www.morphotek.com.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 9,000 people worldwide.
###